Hookipa Pharma Inc (NASDAQ:HOOK) Short Interest Update

Hookipa Pharma Inc (NASDAQ:HOOK) saw a large decrease in short interest in the month of March. As of March 31st, there was short interest totalling 52,000 shares, a decrease of 26.3% from the March 15th total of 70,600 shares. Based on an average daily volume of 107,300 shares, the short-interest ratio is currently 0.5 days. Approximately 0.8% of the company’s stock are short sold.

Institutional Trading of Hookipa Pharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HOOK. Millennium Management LLC bought a new position in Hookipa Pharma during the fourth quarter worth $31,000. Squarepoint Ops LLC acquired a new stake in Hookipa Pharma in the 4th quarter worth $104,000. Finally, Gilead Sciences Inc. bought a new position in shares of Hookipa Pharma during the 4th quarter worth about $3,771,000. Institutional investors and hedge funds own 63.88% of the company’s stock.

Hookipa Pharma Stock Performance

Shares of NASDAQ:HOOK opened at $0.77 on Friday. The stock’s 50-day moving average is $1.25 and its 200-day moving average is $2.21. The company has a market cap of $9.33 million, a P/E ratio of -0.21 and a beta of 0.78. Hookipa Pharma has a 52-week low of $0.72 and a 52-week high of $10.50.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on HOOK shares. HC Wainwright reiterated a “neutral” rating on shares of Hookipa Pharma in a research report on Friday, January 10th. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and cut their price objective for the company from $48.00 to $2.00 in a research report on Friday, December 20th.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.